Phase 2 VK2735 (VENTURE) shows up to 14.7% weight loss in 13 weeks with dose-dependent efficacy

Viking Therapeutics/VK2735

Viking reported positive phase 2 results for VK2735, showing dose-dependent weight loss up to 14.7% from baseline after 13 weeks. Adverse events were mostly mild-to-moderate GI symptoms. Results supported advancement to phase 3 trials.

• Weight loss ranged 10% to 14.7% depending on dose, with no plateau at 13 weeks.
• 95% of GI adverse events were mild or moderate; nausea declined with continued dosing.
• Dual GLP-1/GIP strategy demonstrated clear benefit over single-pathway agonists.
• All primary and secondary efficacy endpoints achieved.